HIV-1 Drug Resistance Mechanisms and Implications

HIV-1 drug resistance emerges when mutations in viral enzymes reduce the binding or efficacy of antiretroviral agents, undermining therapy and enabling transmission of resistant strains. Resistance mechanisms principally affect four drug classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors and integrase strand transfer inhibitors. Mutations may alter enzyme active sites, modify drug-binding pockets or compensate for fitness costs, leading to virological failure and limited future treatment options. Minority resistance variants, undetectable by standard assays, can expand under drug pressure and precipitate rebound viremia. The global rise in pretreatment resistance—especially to non-nucleoside reverse transcriptase inhibitors—has driven shifts towards regimens with higher genetic barriers and reinforced the importance of routine surveillance, adherence support and point-of-care resistance testing to sustain long-term viral suppression and curb onward transmission.

Research from Nature Portfolio

Recent studies in rural South Africa have combined deep sequencing with phylogenetic and geospatial analyses across over 18 000 individuals to map transmission networks and resistance profiles. Findings reveal persistent resistance to older reverse transcriptase inhibitors and concerning non-nucleoside reverse transcriptase inhibitor mutations in antiretroviral-naïve populations, while integrase strand transfer inhibitor resistance remains scarce. Transmission clusters are more prevalent in peripheral and rural communities, underscoring the need for targeted screening for rilpivirine resistance before deploying long-acting injectable regimens and for geographically focused interventions to interrupt local transmission chains.

HIV-1 Drug Resistance Mechanisms and Implications publication trend

The graph below shows the total number of articles in hiv-1 drug resistance mechanisms and implications across all publications each year (not limited to Nature Index journals).

Technical terms

Antiretroviral therapy (ART): Combination of drugs used to suppress HIV replication and prevent disease progression.

Integrase strand transfer inhibitors (INSTIs): Drugs that block integration of viral DNA into the host genome by targeting integrase.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Agents that bind allosterically to reverse transcriptase, inhibiting viral DNA synthesis.

Minority variants: Low-frequency viral strains carrying resistance mutations undetected by conventional genotyping.

Deep sequencing: High-throughput method that detects low-abundance viral variants with high sensitivity.

Phylogenetic analysis: Reconstruction of evolutionary relationships to infer patterns of viral transmission.

References

1. Current Perspectives on HIV-1 Antiretroviral Drug Resistance. Viruses (2014).
2. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel. Clinical Infectious Diseases (2018).
3. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. The Lancet Infectious Diseases (2017).
4. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy. PLOS Medicine (2008).
5. HIV transmission dynamics and population-wide drug resistance in rural South Africa. Nature Communications (2024).
6. The molecular epidemiology of HIV-1 in Sweden 1996 to 2022, and the influence of migration from Ukraine. Eurosurveillance (2023).
7. Next‐Generation Sequencing Methods for Near‐Real‐Time Molecular Epidemiology of HIV and HCV. Reviews in Medical Virology (2024).
8. Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1. Bioinformatics (2024).